Xuedan Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xuedan Sun has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Lianxin Liu
Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China
4 shared publications Shixiang Pan
Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, China
4 shared publicationsWanxiang Xiong
Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, China
4 shared publicationsBoyu Chen
Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, China
3 shared publicationsChunxu Wang
Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, China
3 shared publicationsJinyi Zhao
School of Medicine, Anhui University of Science & Technology, Huainan, 232001, China
3 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10042
Metabolic licensing of quiescent glioblastoma activation and immune evasion via astrocyte-mitochondria shuttle
Reactivating quiescent tumor cells at the invasive margin are either eliminated by immune surveillance or expand through immune escape. The mechanisms underpinning phenotypic plasticity driving expansion leading to therapeutic resistance, dissemination, and recurrence remain elusive. Here we establish a metabolic licensing paradigm wherein reactive astrocytes awaken dormant glioblastoma cells and simultaneously confer immune evasion through intercellular mitochondrial transfer. Astrocyte-derived mitochondria, enriched with the one carbon metabolism enzyme SHMT2, deliver functional metabolic units that reprogram recipient glioma cells. This shuttled cargo fuels S adenosylmethionine production, driving m⁶A RNA methylation and release of paused RNA polymerase II over a specific set of genes. Ribosome biogenesis and focal adhesion pathways are selectively upregulated consequently, which enables rapid proliferation and immune resistance of tumour cells. Genetic ablation of astrocytic Shmt2 or pharmacological blockade of mitochondrial transfer suppresses quiescent cell reactivation and delays tumor progression. Our findings thus establish the astrocyte-mitochondria shuttle as a core vulnerability in glioblastomas, linking metabolic crosstalk to epitranscriptomic control of reactivation and immune escape.
- 21 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10042
Open AccessMetabolic licensing of quiescent glioblastoma activation and immune evasion via astrocyte-mitochondria shuttle
Reactivating quiescent tumor cells at the invasive margin are either eliminated by immune surveillance or expand through immune escape. The mechanisms underpinning phenotypic plasticity driving expansion leading to therapeutic resistance, dissemination, and recurrence remain elusive. Here we establish a metabolic licensing paradigm wherein reactive astrocytes awaken dormant glioblastoma cells and simultaneously confer immune evasion through intercellular mitochondrial transfer. Astrocyte-derived mitochondria, enriched with the one carbon metabolism enzyme SHMT2, deliver functional metabolic units that reprogram recipient glioma cells. This shuttled cargo fuels S adenosylmethionine production, driving m⁶A RNA methylation and release of paused RNA polymerase II over a specific set of genes. Ribosome biogenesis and focal adhesion pathways are selectively upregulated consequently, which enables rapid proliferation and immune resistance of tumour cells. Genetic ablation of astrocytic Shmt2 or pharmacological blockade of mitochondrial transfer suppresses quiescent cell reactivation and delays tumor progression. Our findings thus establish the astrocyte-mitochondria shuttle as a core vulnerability in glioblastomas, linking metabolic crosstalk to epitranscriptomic control of reactivation and immune escape.
- 14 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218654
G4 DNA potentiates KDM2B phase separation to couple transcriptional repression with immune remodeling in hepatocellular carcinoma
- 14 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218654
G4 DNA potentiates KDM2B phase separation to couple transcriptional repression with immune remodeling in hepatocellular carcinoma
- Open Access
- 19 March 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (6)
Development and application of G4-Flame as a visual biosensor for G4-DNA
G-quadruplex DNA (G4-DNA), a noncanonical tetrahelical nucleic acid structure stabilized by stacked G-quartets via Hoogsteen hydrogen bonding, plays critical roles in genomic regulation and disease pathogenesis. Current methodologies for detecting these structures face limitations in specificity, spatiotemporal resolution, and live-cell applicability. To address these challenges, we engineered G4-Flame, a genetically encoded fluorescent biosensor utilizing circularly permuted fluorescent protein technology. By strategically positioning a G4-specific binding domain proximal to the fluorophore of circularly permuted YFP (cpYFP), G4-Flame achieves real-time, high-resolution visualization of G4-DNA dynamics in living systems, with specificity across diverse G4 conformations. Experimental validation revealed distinct spatiotemporal patterns of G4-DNA during the cell cycle: nuclear G4-DNA levels peaked during the S phase, while mitochondrial G4-DNA was found to suppress the expression of mitochondrial-encoded genes. Clinically, serum analysis revealed significantly elevated G4-DNA levels in cancer patients compared to healthy controls. This work establishes G4-Flame as a transformative tool for investigating G4-DNA spatiotemporal regulation and advances its potential as a biomarker for early cancer detection, bridging fundamental research with clinical translation.
- 19 March 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (6)
Open AccessDevelopment and application of G4-Flame as a visual biosensor for G4-DNA
G-quadruplex DNA (G4-DNA), a noncanonical tetrahelical nucleic acid structure stabilized by stacked G-quartets via Hoogsteen hydrogen bonding, plays critical roles in genomic regulation and disease pathogenesis. Current methodologies for detecting these structures face limitations in specificity, spatiotemporal resolution, and live-cell applicability. To address these challenges, we engineered G4-Flame, a genetically encoded fluorescent biosensor utilizing circularly permuted fluorescent protein technology. By strategically positioning a G4-specific binding domain proximal to the fluorophore of circularly permuted YFP (cpYFP), G4-Flame achieves real-time, high-resolution visualization of G4-DNA dynamics in living systems, with specificity across diverse G4 conformations. Experimental validation revealed distinct spatiotemporal patterns of G4-DNA during the cell cycle: nuclear G4-DNA levels peaked during the S phase, while mitochondrial G4-DNA was found to suppress the expression of mitochondrial-encoded genes. Clinically, serum analysis revealed significantly elevated G4-DNA levels in cancer patients compared to healthy controls. This work establishes G4-Flame as a transformative tool for investigating G4-DNA spatiotemporal regulation and advances its potential as a biomarker for early cancer detection, bridging fundamental research with clinical translation.
- 18 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 130-144
IFRD1 orchestrates hepatocyte metabolism and macrophage interactions to facilitate liver regeneration
- 18 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 130-144
IFRD1 orchestrates hepatocyte metabolism and macrophage interactions to facilitate liver regeneration
- Open Access
- 23 October 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (11) , 2396-2409
Bioorthogonal Probe BTD-Az Enables Sensitive and Rapid In Vivo Profiling of Protein Cysteine Sulfenylation
Cysteine sulfenylation (Cys-SOH) is a transient redox-sensitive post-translational modification that regulates protein activity and cellular stress responses, yet its in vivo dynamics remain difficult to capture due to short half-life and low abundance. Here, we report the design and application of BTD-Az, a cell-permeable probe that incorporates an azide handle into the benzothiazine scaffold, enabling rapid bioorthogonal labeling of Cys-SOH both in vivo and in vitro, followed by efficient enrichment through strain-promoted azide-alkyne cycloaddition. This approach streamlines the detection and analysis of Cys-SOH with exceptional specificity and convenience. BTD-Az exhibited negligible cytotoxicity, efficiently enriched sulfenylated proteins in vitro, and achieved direct in vivo labeling in mouse tissues through SPAAC-mediated pull-down. Coupling BTD-Az with 4D-DIA proteomics allowed global sulfenylome profiling, revealing >5000 labeled proteins across tissues. As a proof-of-concept biological application, we applied BTD-Az to aging cartilage and identified 95 proteins with differential sulfenylation, including the mitochondrial enzyme IDH2, whose Cys-SOH modification promoted proteasomal degradation and exacerbated redox imbalance. Collectively, this study establishes BTD-Az as a robust chemical tool for in vivo sulfenylation profiling, providing a broadly applicable platform for redox proteomics and the discovery of redox-sensitive regulatory mechanisms in health and disease.
- 23 October 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (11) , 2396-2409
Open AccessBioorthogonal Probe BTD-Az Enables Sensitive and Rapid In Vivo Profiling of Protein Cysteine Sulfenylation
Cysteine sulfenylation (Cys-SOH) is a transient redox-sensitive post-translational modification that regulates protein activity and cellular stress responses, yet its in vivo dynamics remain difficult to capture due to short half-life and low abundance. Here, we report the design and application of BTD-Az, a cell-permeable probe that incorporates an azide handle into the benzothiazine scaffold, enabling rapid bioorthogonal labeling of Cys-SOH both in vivo and in vitro, followed by efficient enrichment through strain-promoted azide-alkyne cycloaddition. This approach streamlines the detection and analysis of Cys-SOH with exceptional specificity and convenience. BTD-Az exhibited negligible cytotoxicity, efficiently enriched sulfenylated proteins in vitro, and achieved direct in vivo labeling in mouse tissues through SPAAC-mediated pull-down. Coupling BTD-Az with 4D-DIA proteomics allowed global sulfenylome profiling, revealing >5000 labeled proteins across tissues. As a proof-of-concept biological application, we applied BTD-Az to aging cartilage and identified 95 proteins with differential sulfenylation, including the mitochondrial enzyme IDH2, whose Cys-SOH modification promoted proteasomal degradation and exacerbated redox imbalance. Collectively, this study establishes BTD-Az as a robust chemical tool for in vivo sulfenylation profiling, providing a broadly applicable platform for redox proteomics and the discovery of redox-sensitive regulatory mechanisms in health and disease.
- Open Access
- 28 May 2024
- Published by Springer Nature in Cell Discovery
- Vol. 10 (1) , 1-21
IFRD1 promotes tumor cells “low-cost” survival under glutamine starvation via inhibiting histone H1.0 nucleophagy
Glutamine addiction represents a metabolic vulnerability of cancer cells; however, effective therapeutic targeting of the pathways involved remains to be realized. Here, we disclose the critical role of interferon-related developmental regulator 1 (IFRD1) in the adaptive survival of hepatocellular carcinoma (HCC) cells during glutamine starvation. IFRD1 is induced under glutamine starvation to inhibit autophagy by promoting the proteasomal degradation of the key autophagy regulator ATG14 in a TRIM21-dependent manner. Conversely, targeting IFRD1 in the glutamine-deprived state increases autophagy flux, triggering cancer cell exhaustive death. This effect largely results from the nucleophilic degradation of histone H1.0 and the ensuing unchecked increases in ribosome and protein biosynthesis associated with globally enhanced chromatin accessibility. Intriguingly, IFRD1 depletion in preclinical HCC models synergizes with the treatment of the glutaminase-1 selective inhibitor CB-839 to potentiate the effect of limiting glutamine. Together, our findings reveal how IFRD1 supports the adaptive survival of cancer cells under glutamine starvation, further highlighting the potential of IFRD1 as a therapeutic target in anti-cancer applications.
- 28 May 2024
- Published by Springer Nature in Cell Discovery
- Vol. 10 (1) , 1-21
Open AccessIFRD1 promotes tumor cells “low-cost” survival under glutamine starvation via inhibiting histone H1.0 nucleophagy
Glutamine addiction represents a metabolic vulnerability of cancer cells; however, effective therapeutic targeting of the pathways involved remains to be realized. Here, we disclose the critical role of interferon-related developmental regulator 1 (IFRD1) in the adaptive survival of hepatocellular carcinoma (HCC) cells during glutamine starvation. IFRD1 is induced under glutamine starvation to inhibit autophagy by promoting the proteasomal degradation of the key autophagy regulator ATG14 in a TRIM21-dependent manner. Conversely, targeting IFRD1 in the glutamine-deprived state increases autophagy flux, triggering cancer cell exhaustive death. This effect largely results from the nucleophilic degradation of histone H1.0 and the ensuing unchecked increases in ribosome and protein biosynthesis associated with globally enhanced chromatin accessibility. Intriguingly, IFRD1 depletion in preclinical HCC models synergizes with the treatment of the glutaminase-1 selective inhibitor CB-839 to potentiate the effect of limiting glutamine. Together, our findings reveal how IFRD1 supports the adaptive survival of cancer cells under glutamine starvation, further highlighting the potential of IFRD1 as a therapeutic target in anti-cancer applications.